Compositions and methods for regulating cancer-related signaling pathways
OwnerJacek K. Pinskiinventor
Life of this patent
Estimating the term…
Abstract
The use of luteinizing hormone receptor (LHR) as a treatment target in cancer is provided. Data demonstrates that LHR plays an important role in androgen synthesis and signaling pathways critical for prostate cancer progression. When LHR is silenced, there is a significant downregulation of androgen receptor (AR) mRNA and protein expression with a subsequent suppression of PSA expression. Data suggesting that the LH-LHR signaling cascade may be an upstream and viable therapeutic target in castration-resistant prostate cancer (CRPC) is presented.
Claims17
A method for one or more of:
- a. downregulating androgen receptor (AR) mRNA expression and/or AR protein expression;
- b. suppressing prostate (PSA) expression and/or PSA promoter activity;
- c. suppressing the activity of PKA;
- d. suppressing the activity of PI3K/AKT;
- e. suppressing the activity of ERK;
- or
- f. suppressing the expression of HER-2,
- in a cell expressing luteinizing hormone receptor (LHR), comprising contacting the cell with an effective amount of an agent that inhibits the expression of LHR.
A method for treating a cancer or tumor cell expressing luteinizing hormone receptor (LHR), comprising contacting the cell with an effective amount of an agent that inhibits the expression of LHR.
A method to screen for potential therapeutic agents that possess one or more of:
- a. downregulating androgen receptor (AR) mRNA expression and/or AR protein expression;
- b. suppressing prostate (PSA) expression and/or PSA promoter activity;
- c. suppressing the activity of PKA;
- d. suppressing the activity of PI3K/AKT;
- e. suppressing the activity of ERK;
- or
- f. suppressing the expression of HER-2,
- comprising contacting a first cell expressing LHR with a potential therapeutic agent and noting the expression or activity of the expression or activity of one or more of a. to f., with that of a second cell expressing LHR having been contacted with an agent that inhibits the expression of LHR, wherein if the expression or activity of the first cell is the same or better than that of the second cell, the agent is a potential therapeutic agent.
A kit useful for one or more of:
- a. androgen receptor (AR) mRNA expression and/or AR protein expression
- b. prostate (PSA) expression and/or PSA promoter activity;
- c. the activity of PKA;
- d. the activity of PI3K/AKT;
- e. the activity of ERK;
- or
- f. the expression of HER-2,
- comprising an effective amount of an agent that inhibits the expression of LHR and optionally instructions for use.
A method for treating a cancer expressing luteinizing hormone receptor (LHR) in a subject in need thereof, comprising administering to the subject an effective amount of an agent that inhibits the expression of LHR, thereby treating the cancer.
Dependencies are inferred from the claim text.